Table 2 Synoptic view of selected studies of ECT in cSCC

Belehradek M et al., Cancer 1993 [20]

Phase I/II

57

15

73

Allegretti JP et al., Laryngosc, 2001 [16]

Phase I/II

51

36

87

Burian M et al., Acta Otolaringol 2003 [21]

Phase II

83

17

100

Bloom DC et al., Eur J Sur Oncol 2005 [22]

Phase II

25

32

57

Matthiesen LW et al., 2011[23]

Phase II

BLM i.t.&i.v.

Landstrom FJ et al., Acta Otolaryngol, 2011 [24]

24

BLM i.t.

Skarlatos I et al., 2011 [25]

Prospective multicenter

9 (64.2)

4 (28.5)

13 (92.8)

Nd

BLM i.t.&i.v.

Gargiulo M et al., Ann Surg, 2012 [26]

Retrospective

8 (61.5)

5 (38.4)

13 (100)

18 (range 4–48)

BLM i.v.

Mevio N, et al., Tumori, 2012 [27]

Prospective

7 (53.8)

4 (38.4)

11 (84.6)

8 (range 2–20)

BLM i.v.

Benevento R et al., Surgery 2013 [28]

Prospective

5 (50%)

3 (30%)

8 (100)

3

BLM i.v.

Solari N et al., J Surg Oncol, 2014[29]

Prospective

Nd

6

BLM i.v.

Seccia V et al., Anticancer Res, 2014 [30]

Prospective

2 (25)

5 (62)

7 (87)

9 (range 3–12)

BLM i.v.

Campana LG et al., Br J Oral Maxillofac Surg, 2014 [31]

Retrospective

6 (25)

6 (25)

12 (50)

14 (3–82)

BLM i.t.&i.v.

Landstorm FJ et al., Acta Otolaryngol, 2015 [32]

4

4

24

BLM i.t.

Landstorm FJ et al., Acta Otolaryngol, 2015 [33]

Prospective

Nd

(100)

Median 58 months

BLM i.t.

Domanico R et al., Drug Des Devel Ther, 2015 [34]

Experimental

0

3 (75)

3 (75)

1

BLM i.v.

Campana LG et al., EJSO, 2016 [18]

Prospective multicenter

14 (40.7%)

21 (60)

30 (85.2)

1–12 (evaluation at 2 months)

BLM i.v.&i.t., CDDP i.t.

Rotunno R et al., G It Derm Venereol, 2015[35]

Multicenter prospective not randomized phase II

13 (52)

7 (28)

20 (80)

13

BLM i.v.

Bertino G et al. Eur J Cancer, 2016 [36]

Prospective multi center

26/47 (55)

11/47 (24)

37/47 (79)

2

BLM i.t.&i.v.

Di Monta G et al., current study

Retrospective

22.7

59

81.7

34 (range 5–48)

BLM i.v.